Skip to main content
Log in

Reply to “STOX1 is not imprinted and is not likely to be involved in preeclampsia”

  • Correspondence
  • Published:

From Nature Genetics

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Iglesias-Platas, I. et al. Nat. Genet. 39, 279–280 (2007).

    Article  CAS  Google Scholar 

  2. Van Dijk, M. et al. Nat. Genet. 37, 514–519 (2005).

    Article  CAS  Google Scholar 

  3. Oudejans, C.B. et al. Hum. Genet. 120, 607–612 (2007).

    Article  Google Scholar 

  4. Oudejans, C.B. et al. Mol. Hum. Reprod. 10, 589–598 (2004).

    Article  CAS  Google Scholar 

  5. Van Dijk, M. et al. Gene Expr. Patterns 4, 61–65 (2004).

    Article  Google Scholar 

  6. Saleem, R.A. et al. Hum. Mol. Genet. 12, 2993–3005 (2003).

    Article  CAS  Google Scholar 

  7. Lo, Y.M.D. et al. Nat. Med. 13, 218–223 (2007).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

Y.M.D.L. and S.S.C. have filed patent applications on epigenetic markers for prenatal monitoring. The VU Medical Center has filed a patent application related to a method for diagnosing preeclampsia.

Supplementary information

Supplementary Fig. 1

The STOX1 CpG island is unmethylated.

Supplementary Methods

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Dijk, M., van Bezu, J., Chim, S. et al. Reply to “STOX1 is not imprinted and is not likely to be involved in preeclampsia”. Nat Genet 39, 280–281 (2007). https://doi.org/10.1038/ng0307-280

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng0307-280

  • Springer Nature America, Inc.

Navigation